Aptose Biosciences Inc. Stock price

Equities

APS

CA03835T3091

Biotechnology & Medical Research

Delayed Toronto S.E. 11:10:24 2024-03-28 am EDT 5-day change 1st Jan Change
2.17 CAD +5.85% Intraday chart for Aptose Biosciences Inc. +2.84% -35.22%
Sales 2024 * - Sales 2025 * 2.08M 1.54M Capitalization 32.22M 23.8M
Net income 2024 * -84M -62.05M Net income 2025 * -39M -28.81M EV / Sales 2024 * -
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 15.5 x
P/E ratio 2024 *
-0.24 x
P/E ratio 2025 *
-0.37 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 79.74%
More Fundamentals * Assessed data
Dynamic Chart
Aptose Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Transcript : Aptose Biosciences Inc., Q4 2023 Earnings Call, Mar 26, 2024
Aptose Biosciences Up 3% After Hours as its 2023 Loss Widens on Higher R&D Spending MT
Aptose Biosciences Brief: Says Luxeptinib G3 Formulation Achieved "Desired Levels and Positions for Future Trials" MT
Aptose Biosciences Brief: Says Tuspetinib to Advance to TUS+VEN+HMA Triplet Therapy Pilot Study in 1L AML; Adds Tuspetinib "Continues Broad Activity Across Mutations with Excellent Safety Profile" MT
Aptose Biosciences Brief: Q4 Basic and diluted loss per Common Share US$7.58 MT
Aptose Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
North American Morning Briefing : Markets Steady -2- DJ
North American Morning Briefing : Stock Futures -2- DJ
Top Premarket Gainers MT
Aptose Biosciences Down 3% After Hours as it Raises US$13.7 Million in a Bought-Deal Offering, Private Placement MT
Aptose Biosciences Raises US$13.7 Million in a Bought-Deal Offering of Share Units and Concurrent Private Placement MT
Aptose Biosciences Brief: Announcing Closing of US$9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option MT
Aptose Biosciences Inc. announced that it has received $4 million in funding from Hanmi Pharm. Co., Ltd. CI
Wall Street Set to Open Marginally Lower Friday; December Inflation Data Lower Than Forecast MT
More news
1 day+5.85%
1 week+2.84%
Current month-9.58%
1 month-12.50%
3 months-33.44%
6 months-42.29%
Current year-35.22%
More quotes
1 week
2.01
Extreme 2.01
2.17
1 month
1.85
Extreme 1.85
2.57
Current year
1.85
Extreme 1.85
3.48
1 year
1.85
Extreme 1.85
13.35
3 years
1.85
Extreme 1.85
122.10
5 years
1.85
Extreme 1.85
189.30
10 years
1.85
Extreme 1.85
189.30
More quotes
Managers TitleAgeSince
Chief Executive Officer 65 13-10-27
Director of Finance/CFO 61 22-06-26
Chief Operating Officer - 21-10-24
Members of the board TitleAgeSince
Director/Board Member 80 07-09-18
Director/Board Member 67 22-09-12
Director/Board Member 71 07-09-18
More insiders
Date Price Change Volume
24-03-28 2.17 +5.85% 3 500
24-03-27 2.05 -3.76% 7,400
24-03-26 2.13 +3.90% 1,501
24-03-25 2.05 -1.91% 2,340
24-03-22 2.09 -0.95% 9,133

Delayed Quote Toronto S.E., March 28, 2024 at 11:10 am EDT

More quotes
Aptose Biosciences Inc. is a clinical-stage biotechnology company. The Company is engaged in the development and commercialization of precision medicines addressing unmet clinical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage oral kinase inhibitors under development for hematologic malignancies: tuspetinib (HM43239), an oral, myeloid kinase inhibitor being studied as monotherapy and in combination therapy in the APTIVATE international Phase I/II expansion trial in patients with relapsed or refractory acute myeloid leukemia (AML); and luxeptinib (CG-806), an oral, dual lymphoid and myeloid kinase inhibitor in Phase I a/b stage development for the treatment of patients with relapsed or refractory hematologic malignancies.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
2.05
Average target price
-
Consensus
  1. Stock
  2. Equities
  3. Stock Aptose Biosciences Inc. - Toronto S.E.